Accessibility Menu
GridAI Technologies logo

GridAI Technologies

(NASDAQ) GRDX

Current Price$3.20
Market Cap$22.12MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2025)-25%
5 Year-100%
1 Year+126%
1 Month-41%
GridAI Technologies last closing stock price
MetricPriceDate
Last closeUSD 3.202026-07-20
GridAI Technologies stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-21.38%USD 4.072026-07-13
1 month-40.74%USD 5.402026-06-18
3 month+32.23%USD 2.422026-04-21
Year to date-31.33%USD 4.662025-12-31
1 year+125.61%USD 1.422025-07-18
3 year-91.63%USD 38.222023-07-21
5 year-100%USD 93,121.682021-07-21
Since inception-24.71%USD 4.252025-10-31

GridAI Technologies Financials at a Glance

Market Cap

$22.12MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$74.46K

Net Income (TTM)

-$8.69M

EPS (TTM)

-$2.97

P/E Ratio

-1.08

Dividend

$0.00

Beta (Volatility)

0.45 (Low)

Price

$3.20

Volume

1

Open

$3.82

Previous Close

$3.20

Daily Range

$3.19 - $3.82

52-Week Range

$1.08 - $6.93

Estimated Earnings Date

Aug 17, 2026

GRDX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About GridAI Technologies

Entero Therapeutics develops oral medicines for digestive diseases. Its main product helps people digest fats when their pancreas does not work well. The company aims to make treatment easier for patients with chronic stomach problems.

Products and Services

  • Adrulipase: Oral enzyme for people with pancreatic disorders; 0% of revenue (no sales).
  • Latiglutenase: Pill for celiac disease, breaks down gluten; 0% of revenue (discontinued).
  • CypCel: Tool to monitor gut health in celiac patients; 0% of revenue (discontinued).
  • Capeserod: Drug for delayed stomach emptying (gastroparesis); 0% of revenue (development ended).
  • Niclosamide: Anti-inflammatory pill for bowel diseases; 0% of revenue (not active).

Growth and Expansion

  • Acquired ImmunogenX in March 2024, adding celiac-focused products.
  • Unwound ImmunogenX deal by June 2025; assets now held for sale.
  • Terminated Sanofi license for Capeserod in February 2025.
  • Raised approximately $4.5 million in net proceeds in March 2024 and $1.1 million in gross proceeds in May 2024 via direct offerings.
  • Entered into a $2 million revolving loan agreement in January 2025, with $700,000 initially drawn to support operations.

What Makes Entero Therapeutics Stand Out

Entero focuses on medicines that work only in the gut, aiming to reduce side effects. Its main drug, Adrulipase, is not made from animals, which is rare for this treatment area. The company has a history of trying new partnerships and acquisitions, though most have not led to lasting products.

Five Things You Need to Know

  • Revenue was $0 in Q2 2025, unchanged from Q2 2024 (no product sales).
  • Operating loss was $638,864 in Q2 2025, improved by 81.4% from Q2 2024.
  • Net loss was $998,271 in Q2 2025, improved by 88.7% from Q2 2024.
  • Cash and cash equivalents were $6 million as of Q2 2025, down 25.8% from Q2 2024.

Bottom Line

Entero has narrowed its focus to one main drug after several discontinued projects. The company faces ongoing financial challenges and relies on new funding to continue operations.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

2

CEO

Jason D. Sawyer

Website

www.enterothera.com

Headquarters

Boca Raton, FL 33431, US

GRDX Financials

Key Financial Metrics (TTM)

Gross Margin

-775.58%

Operating Margin

-13264.41%

Net Income Margin

-11664.78%

Return on Equity

-18.69%

Return on Capital

-27.27%

Return on Assets

-18.11%

Earnings Yield

-92.59%

Dividend Yield

0.00%

Payout Ratio

-3.77%

Stock Overview

Market Cap

$22.12MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

6.91M

Volume

1

Avg. Volume

108.88K

Financials (TTM)

Gross Profit

-$577.49K

Operating Income

-$9.88M

EBITDA

-$8.32M

Operating Cash Flow

-$6.67M

Capital Expenditure

$0.00

Free Cash Flow

-$6.67M

Cash & ST Invst.

$385.54K

Total Debt

$2.59M

GridAI Technologies Performance Analysis

GridAI Technologies annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 36,251N/A
GridAI Technologies sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-315.4%
GridAI Technologies annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1,250.80-99.0%
20232023-12-31USD -143.63-88.5%
20242024-12-31USD -15.98-88.9%
20252025-12-31USD -4.16-74.0%
GridAI Technologies sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3025.0%
Q32025-09-30-257.1%
Q42025-12-31-289.3%
Q12026-03-3171.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$38.21K

N/A

Gross Profit

-$613.74K

N/A

Gross Margin

-16.06%

N/A

Market Cap

$22.12MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$11.06M

N/A

Employees

2

N/A

Net Income

-$3.55M

-182.0%

EBITDA

-$2.64M

-183.8%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$385.54K

+549.6%

Total Debt

$2.59M

+210.2%

Accounts Receivable

$1.88M

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$2.59M

+210.2%

Return on Assets

-18.11%

N/A

Return on Invested Capital

-31.12%

N/A

Free Cash Flow

-$1.79M

-118.3%

Operating Cash Flow

-$1.79M

-118.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CINGCingulate Inc.
$4.56+0.44%
ALLRAllarity Therapeutics, Inc.
$1.17-1.68%
ATHAAthira Pharma, Inc.
$6.75-6.12%
LPTXLeap Therapeutics, Inc.
$0.77-3.15%

Trending Stocks

Symbol / CompanyPricePrice Chg
PATHUiPath
$12.16+0.00%
TAT&T
$21.95+0.01%
JOBYJoby Aviation
$7.47+0.03%
WBDWarner Bros. Discovery
$25.86-0.04%

Questions About GRDX

What is the current price of GridAI Technologies?

GridAI Technologies is trading at $3.20 per share.

What is the 52-week range for GridAI Technologies?

Over the past 52 weeks, GridAI Technologies has traded between $1.08 and $6.93.

How much debt does GridAI Technologies have?

As of the most recent reporting period, GridAI Technologies reported total debt of $2.49M.

How much cash does GridAI Technologies have on hand?

GridAI Technologies reported $385.54K in cash and cash equivalents in its most recent financial results.

What is GridAI Technologies’s dividend yield?

GridAI Technologies does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services